Skip to content

Can you travel while on keynote 522 treatments

    What is the keynote-522 regimen?

    KEYNOTE-522 is a phase 3 trial evaluating the immune checkpoint inhibitor pembrolizumab plus neoadjuvant chemotherapy as compared with neoadjuvant chemotherapy alone, followed by the receipt of adjuvant pembrolizumab or placebo, respectively, in patients with early triple-negative breast cancer

    Screenshot of website

    What is a triple-negative cancer?

    The term triple-negative breast cancer refers to the fact that the cancer cells don’t have estrogen or progesterone receptors (ER or PR) and also don’t make any or too much of the protein called HER2. (The cells test “negative” on all 3 tests.)

    Screenshot of website

    What is a pathological complete response?

    Listen to pronunciation. (PA-thuh-LAH-jik kum-PLEET reh-SPONTS) The lack of all signs of cancer in tissue samples removed during surgery or biopsy after treatment with radiation or chemotherapy.

    Screenshot of website

    What does KEYTRUDA do?

    A drug that binds to the protein PD-1 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that express the protein PD-L1, that have certain mutations (changes) in genes involved in DNA repair, or that have a high number of tumor mutations.

    Screenshot of website

    What does event free survival mean?

    Listen to pronunciation. (eh-VENT ? ser-VY-vul) In cancer, the length of time after primary treatment for a cancer ends that the patient remains free of certain complications or events that the treatment was intended to prevent or delay.

    Screenshot of website

    What are the side effects of Pembrolizumab?

    Common side effects of KEYTRUDA when used alone include: feeling tired, pain, including pain in muscles, rash, diarrhea, fever, cough, decreased appetite, itching, shortness of breath, constipation, bones or joints and stomach-area (abdominal) pain, nausea, and low levels of thyroid hormone.

    Screenshot of website

    Can you survive triple-negative cancer?

    In general, about 91% of all women with triple-negative breast cancer are still alive 5 years after diagnosis. If the cancer has spread to the lymph nodes near the breast (regional) the 5 year relative survival rate is about 65%. If the cancer has spread to distant places, the 5 year relative survival rate is 12%.

    Screenshot of website

    How long can you live with triple-negative?

    It’s one of the most challenging breast cancers to treat. But researchers are making steady progress toward more effective treatments. Overall, 77% of women who have triple negative breast cancer are alive five years after diagnosis.

    Screenshot of website

    What is considered a good response to chemo?

    Complete response – all of the cancer or tumor disappears; there is no evidence of disease. A tumor marker (if applicable) may fall within the normal range. Partial response – the cancer has shrunk by a percentage but disease remains. A tumor marker (if applicable) may have fallen but evidence of disease remains.

    Screenshot of website

    Does a pathologic complete response mean cured?

    Pathological complete response (pCR) is defined as disappearance of all invasive cancer in the breast after completion of neoadjuvant chemotherapy, although some authors require clearance of residual disease in axillary nodes as well (von Minckwitz et al., 2012).

    Screenshot of website

    How much longer do KEYTRUDA patients live?

    Overall survival duration with Keytruda was 28 months versus 11 months for chemotherapy in patients with any KRAS mutation.

    Screenshot of website

    What are the signs that immunotherapy is working?

    In general, a positive response to immunotherapy is measured by a shrinking or stable tumor. Although treatment side effects such as inflammation may be a sign that immunotherapy is affecting the immune system in some way, the precise link between immunotherapy side effects and treatment success is unclear.

    Screenshot of website

    How long does immunotherapy extend life?

    Generally, at 2 years, if patients have done well on therapy, and you have 2 years of ongoing disease control, in most patients we are stopping at 2 years and then monitoring them.

    Screenshot of website

    What is the survival rate after immunotherapy?

    In this study, the mortality rate in the first 30 days after immunotherapy was 15%, which is a high rate compared with RCTs and with our study. However, this study included patients with both lung cancer and mesothelioma, and almost all the patients had previously received systemic chemotherapy.

    Screenshot of website

    What is the next step after immunotherapy?

    Chemotherapy. This uses a powerful combination of drugs to kill or stop the growth of cancer cells. You get the medicine by mouth or through a vein. Targeted therapy.

    Screenshot of website

    Is immunotherapy the last resort?

    What would happen if immunotherapy was the first approach, for all patients? Immunotherapy is still proving itself. It’s often used as a last resort, once other therapies have reached the end of their effectiveness.

    Screenshot of website

    Videos